Brown Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.1M Buy
199,765
+2,946
+1% +$172K 0.02% 397
2025
Q4
$10.6M Sell
196,819
-23,582
-11% -$1.13M 0.01% 417
2025
Q3
$9.94M Buy
220,401
+1,223
+0.6% +$57.1K 0.01% 420
2025
Q2
$10.1M Sell
219,178
-1,867
-0.8% -$91.6K 0.01% 406
2025
Q1
$13.5M Sell
221,045
-3,355
-1% -$196K 0.02% 360
2024
Q4
$12.7M Sell
224,400
-3,973
-2% -$222K 0.02% 386
2024
Q3
$11.8M Sell
228,373
-3,524
-2% -$165K 0.01% 398
2024
Q2
$9.63M Buy
231,897
+9,744
+4% +$436K 0.01% 420
2024
Q1
$12M Sell
222,153
-2,295
-1% -$117K 0.02% 394
2023
Q4
$11.5M Sell
224,448
-17,057
-7% -$895K 0.02% 389
2023
Q3
$14M Sell
241,505
-2,133
-0.9% -$131K 0.02% 352
2023
Q2
$15.6M Sell
243,638
-8,248
-3% -$553K 0.02% 340
2023
Q1
$17.5M Buy
251,886
+1,725
+0.7% +$122K 0.03% 330
2022
Q4
$18M Buy
250,161
+4,051
+2% +$305K 0.03% 324
2022
Q3
$17.5M Buy
246,110
+29,673
+14% +$2.15M 0.03% 321
2022
Q2
$16.7M Buy
216,437
+6,376
+3% +$486K 0.03% 321
2022
Q1
$15.3M Sell
210,061
-34,750
-14% -$2.33M 0.02% 345
2021
Q4
$15.3M Buy
244,811
+29,247
+14% +$1.72M 0.02% 357
2021
Q3
$12.8M Sell
215,564
-1,369
-0.6% -$90.2K 0.02% 346
2021
Q2
$14.5M Buy
216,933
+5,395
+3% +$352K 0.02% 336
2021
Q1
$13.4M Sell
211,538
-3,011
-1% -$187K 0.02% 314
2020
Q4
$13.3M Sell
214,549
-4,746
-2% -$292K 0.02% 300
2020
Q3
$13.2M Sell
219,295
-8,091
-4% -$487K 0.03% 280
2020
Q2
$13.4M Buy
227,386
+2,550
+1% +$153K 0.03% 272
2020
Q1
$12.5M Buy
224,836
+21,043
+10% +$1.29M 0.04% 249
2019
Q4
$13.1M Buy
203,793
+14,726
+8% +$843K 0.03% 293
2019
Q3
$9.59M Sell
189,067
-5,042
-3% -$237K 0.03% 324
2019
Q2
$8.8M Sell
194,109
-34,358
-15% -$1.6M 0.03% 333
2019
Q1
$10.9M Sell
228,467
-6,731
-3% -$335K 0.03% 338
2018
Q4
$12.2M Sell
235,198
-31,595
-12% -$1.7M 0.04% 299
2018
Q3
$16.6M Sell
266,793
-6,345
-2% -$377K 0.05% 275
2018
Q2
$15.1M Sell
273,138
-26,033
-9% -$1.41M 0.05% 268
2018
Q1
$18.9M Sell
299,171
-16,874
-5% -$1.09M 0.06% 237
2017
Q4
$19.4M Buy
316,045
+11,901
+4% +$744K 0.06% 239
2017
Q3
$19.4M Buy
304,144
+23,631
+8% +$1.38M 0.06% 233
2017
Q2
$15.6M Sell
280,513
-10,655
-4% -$580K 0.05% 252
2017
Q1
$15.8M Sell
291,168
-24,550
-8% -$1.35M 0.05% 243
2016
Q4
$18.4M Sell
315,718
-24,851
-7% -$1.36M 0.07% 215
2016
Q3
$18.4M Sell
340,569
-7,755,824
-96% -$498M 0.06% 210
2016
Q2
$595M Sell
8,096,393
-428,543
-5% -$30.3M 2.09% 7
2016
Q1
$545M Sell
8,524,936
-16,688
-0.2% -$1.05M 1.88% 14
2015
Q4
$588M Buy
8,541,624
+433,894
+5% +$28.7M 1.99% 9
2015
Q3
$480M Buy
8,107,730
+248,831
+3% +$15.8M 1.71% 17
2015
Q2
$523M Buy
7,858,899
+730,906
+10% +$48.2M 1.7% 19
2015
Q1
$460M Buy
7,127,993
+921,083
+15% +$57.7M 1.46% 27
2014
Q4
$366M Buy
6,206,910
+5,919,161
+2,057% +$334M 1.16% 26
2014
Q3
$14.7M Buy
287,749
+76,432
+36% +$3.82M 0.05% 225
2014
Q2
$10.3M Sell
211,317
-11,880
-5% -$585K 0.03% 257
2014
Q1
$11.6M Buy
223,197
+32,351
+17% +$1.72M 0.04% 241
2013
Q4
$10.1M Buy
190,846
+59,316
+45% +$3.02M 0.03% 248
2013
Q3
$6.09M Sell
131,530
-3,576
-3% -$157K 0.02% 290
2013
Q2
$6.04M Buy
+135,106
New +$5.87M 0.02% 279

Other funds holding BMY

Brown Advisory's BMY Position: Q1 2026 in Review

Brown Advisory increased its Bristol-Myers Squibb (BMY) stake by 1.5% in Q1 2026, buying an estimated $172K and bringing the position to 199,765 shares worth $12.1M. The position accounts for 0.02% of the portfolio, ranked #397.

Brown Advisory first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $595M in Q2 2016. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Brown Advisory held 199,765 shares of Bristol-Myers Squibb worth $12.1M as of Q1 2026.
  • Brown Advisory bought 2,946 Bristol-Myers Squibb shares in Q1 2026, an estimated $172K.
  • Bristol-Myers Squibb made up 0.02% of Brown Advisory's portfolio in Q1 2026, its #397 holding.
  • Brown Advisory first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Brown Advisory's Bristol-Myers Squibb position peaked at $595M in Q2 2016.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.